187 related articles for article (PubMed ID: 2553829)
1. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
Spiegel RJ; Jacobs SL; Treuhaft MW
J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
Bekisz JB; zur Nedden DL; Enterline JC; Zoon KC
J Interferon Res; 1989 Sep; 9 Suppl 1():S1-7. PubMed ID: 2809275
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
[TBL] [Abstract][Full Text] [Related]
4. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
5. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
Itri LM; Sherman MI; Palleroni AV; Evans LM; Tran LL; Campion M; Chizzonite R
J Interferon Res; 1989 Sep; 9 Suppl 1():S9-15. PubMed ID: 2681444
[TBL] [Abstract][Full Text] [Related]
6. Minimal antigenicity of intron A in human recipients demonstrated by three analytical methods.
Jacobs SJ; Sullivan LM; Salfi M; Grossberg H; Spiegel RJ; Leibowitz PJ; Oden EM; Kelsey DK; Treuhaft MW
J Biol Response Mod; 1988 Oct; 7(5):447-56. PubMed ID: 3183684
[TBL] [Abstract][Full Text] [Related]
7. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
9. [Anti-interferon antibody in chronic hepatitis C].
Arai K; Shindo M; Okuno T
Nihon Rinsho; 1994 Jul; 52(7):1929-34. PubMed ID: 7521441
[TBL] [Abstract][Full Text] [Related]
10. Detection and incidence of neutralizing antibodies to interferon-alpha-n1.
Weck PK; Leventhal BG; Brand C; Finter NB
J Interferon Res; 1989 Sep; 9 Suppl 1():S37-43. PubMed ID: 2553830
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
Larocca AP; Leung SC; Marcus SG; Colby CB; Borden EC
J Interferon Res; 1989 Sep; 9 Suppl 1():S51-60. PubMed ID: 2809278
[TBL] [Abstract][Full Text] [Related]
12. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
Steis RG; Smith JW; Urba WJ; Clark JW; Itri LM; Evans LM; Schoenberger C; Longo DL
N Engl J Med; 1988 Jun; 318(22):1409-13. PubMed ID: 3367950
[TBL] [Abstract][Full Text] [Related]
13. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
Steis RG; Smith JW; Urba WJ; Venzon DJ; Longo DL; Barney R; Evans LM; Itri LM; Ewel CH
Blood; 1991 Feb; 77(4):792-8. PubMed ID: 1704264
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
Antonelli G; Currenti M; Turriziani O; Dianzani F
J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
[TBL] [Abstract][Full Text] [Related]
16. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A).
Spiegel RJ; Spicehandler JR; Jacobs SL; Oden EM
Am J Med; 1986 Feb; 80(2):223-8. PubMed ID: 3484902
[TBL] [Abstract][Full Text] [Related]
17. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
18. Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.
Bell JB; Barfoot R; Iveson T; Powles RL; Millar BC
Br J Cancer; 1994 Oct; 70(4):646-51. PubMed ID: 7917911
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Interferon Alpha-2b is a High-Affinity Antigen for Type 1 Diabetes Autoantibodies.
Khan WA
Can J Diabetes; 2017 Apr; 41(2):217-223. PubMed ID: 28024793
[TBL] [Abstract][Full Text] [Related]
20. The interferon-alpha 2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-alpha 2a.
Hosoi H; Imai M; Yamanaka M
J Gastroenterol Hepatol; 1992; 7(4):411-6. PubMed ID: 1515568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
